Shopping Cart 0
Cart Subtotal
USD 0

Fibrosis-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Fibrosis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis-Pipeline Review, H2 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.

Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 29, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Fibrosis-Overview 7

Fibrosis-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Fibrosis-Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Fibrosis-Companies Involved in Therapeutics Development 28

Acceleron Pharma Inc 28

Aelis Farma SAS 28

Anima Biotech Ltd 28

Bristol-Myers Squibb Company 29

Cellmid Ltd 29

Clementia Pharmaceuticals Inc 30

Complexa Inc 30

Confo Therapeutics 31

EA Pharma Co Ltd 31

Five Prime Therapeutics Inc 31

Genfit SA 32

GlycoMimetics Inc 32

iBio Inc 33

Inception Sciences Inc 33

Isarna Therapeutics GmbH 34

Kadmon Corp LLC 34

Kalyra Pharmaceuticals Inc 34

Morphic Therapeutic Inc 35

Neumedicines Inc 35

Novartis AG 36

Palatin Technologies Inc 36

Proximagen Ltd 37

Redx Pharma Plc 37

Ribomic Inc 37

Scholar Rock Inc 38

SciFluor Life Sciences LLC 38

SK Chemicals Co Ltd 38

Symic Biomedical Inc 39

Fibrosis-Drug Profiles 40

ACE-2798-Drug Profile 40

AEF-0118-Drug Profile 41

AK-002-Drug Profile 42

Antisense RNAi Oligonucleotide to Inhibit HSP47 for Fibrosis-Drug Profile 43

CAB-101-Drug Profile 44

CALY-001-Drug Profile 46

CWHM-12-Drug Profile 47

Drugs for Fibrosis-Drug Profile 48

elafibranor-Drug Profile 49

G-XXX-Drug Profile 57

IB-DMD-Drug Profile 58

IBIOCFB-03-Drug Profile 59

ISTH-1106-Drug Profile 62

KL-01045-Drug Profile 63

Monoclonal Antibodies for Fibrosis-Drug Profile 64

Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis-Drug Profile 65

Monoclonal Antibody 2 for Fibrosis-Drug Profile 66

Monoclonal Antibody for Fibrotic Scar-Drug Profile 67

Monoclonal Antibody to Activate BMP7 for Fibrosis-Drug Profile 68

NCE-401-Drug Profile 69

Neumomir-Drug Profile 70

NMIL-121-Drug Profile 71

PAT-048-Drug Profile 75

phenylbutyrate-Drug Profile 76

PL-5028-Drug Profile 77

PRI-724-Drug Profile 78

Proteins for Central Nervous System Disorders and Fibrosis-Drug Profile 80

RBM-003-Drug Profile 81

RBM-007-Drug Profile 82

SB-061-Drug Profile 83

Small Molecule for Fibrosis-Drug Profile 85

Small Molecule for Fibrosis-Drug Profile 86

Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases-Drug Profile 87

Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease-Drug Profile 88

Small Molecule to Inhibit MGAT2 for Metabolic Disorders and Fibrotic Diseases-Drug Profile 89

Small Molecule to Inhibit MicroRNA for Vascular Fibrosis-Drug Profile 90

Small Molecule to Inhibit ROCK2 for Fibrotic Diseases-Drug Profile 91

Small Molecules for Fibrosis-Drug Profile 92

Small Molecules for Fibrosis-Drug Profile 93

Small Molecules for Fibrosis-Drug Profile 94

Small Molecules for Fibrosis-Drug Profile 95

Small Molecules for Fibrosis-Drug Profile 96

Small Molecules for Fibrosis and Inflammatory Diseases-Drug Profile 97

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis-Drug Profile 98

Small Molecules to Agonize GPCR for Fibrosis-Drug Profile 99

Small Molecules to Agonize RARG for Fibrosis-Drug Profile 100

Small Molecules to Antagonize Integrin Alpha V for Fibrosis-Drug Profile 101

Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease-Drug Profile 102

Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology-Drug Profile 103

SRI-31277-Drug Profile 104

ST-2001-Drug Profile 105

ST-2022-Drug Profile 106

Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology-Drug Profile 107

TTX-330-Drug Profile 108

X-165-Drug Profile 109

XOMA-089-Drug Profile 110

Fibrosis-Dormant Projects 111

Fibrosis-Product Development Milestones 114

Featured News & Press Releases 114

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118


List Of Figure

List of Figures

Number of Products under Development for Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Fibrosis-Pipeline by Acceleron Pharma Inc, H2 2017

Fibrosis-Pipeline by Aelis Farma SAS, H2 2017

Fibrosis-Pipeline by Anima Biotech Ltd, H2 2017

Fibrosis-Pipeline by Bristol-Myers Squibb Company, H2 2017

Fibrosis-Pipeline by Cellmid Ltd, H2 2017

Fibrosis-Pipeline by Clementia Pharmaceuticals Inc, H2 2017

Fibrosis-Pipeline by Complexa Inc, H2 2017

Fibrosis-Pipeline by Confo Therapeutics, H2 2017

Fibrosis-Pipeline by EA Pharma Co Ltd, H2 2017

Fibrosis-Pipeline by Five Prime Therapeutics Inc, H2 2017

Fibrosis-Pipeline by Genfit SA, H2 2017

Fibrosis-Pipeline by GlycoMimetics Inc, H2 2017

Fibrosis-Pipeline by iBio Inc, H2 2017

Fibrosis-Pipeline by Inception Sciences Inc, H2 2017

Fibrosis-Pipeline by Isarna Therapeutics GmbH, H2 2017

Fibrosis-Pipeline by Kadmon Corp LLC, H2 2017

Fibrosis-Pipeline by Kalyra Pharmaceuticals Inc, H2 2017

Fibrosis-Pipeline by Morphic Therapeutic Inc, H2 2017

Fibrosis-Pipeline by Neumedicines Inc, H2 2017

Fibrosis-Pipeline by Novartis AG, H2 2017

Fibrosis-Pipeline by Palatin Technologies Inc, H2 2017

Fibrosis-Pipeline by Proximagen Ltd, H2 2017

Fibrosis-Pipeline by Redx Pharma Plc, H2 2017

Fibrosis-Pipeline by Ribomic Inc, H2 2017

Fibrosis-Pipeline by Scholar Rock Inc, H2 2017

Fibrosis-Pipeline by SciFluor Life Sciences LLC, H2 2017

Fibrosis-Pipeline by SK Chemicals Co Ltd, H2 2017

Fibrosis-Pipeline by Symic Biomedical Inc, H2 2017

Fibrosis-Dormant Projects, H2 2017

Fibrosis-Dormant Projects, H2 2017 (Contd..1), H2 2017

Fibrosis-Dormant Projects, H2 2017 (Contd..2), H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Fibrosis Therapeutic Products under Development, Key Players in Fibrosis Therapeutics, Fibrosis Pipeline Overview, Fibrosis Pipeline, Fibrosis Pipeline Assessment


Companies

Acceleron Pharma Inc

Aelis Farma SAS

Anima Biotech Ltd

Bristol-Myers Squibb Company

Cellmid Ltd

Clementia Pharmaceuticals Inc

Complexa Inc

Confo Therapeutics

EA Pharma Co Ltd

Five Prime Therapeutics Inc

Genfit SA

GlycoMimetics Inc

iBio Inc

Inception Sciences Inc

Isarna Therapeutics GmbH

Kadmon Corp LLC

Kalyra Pharmaceuticals Inc

Morphic Therapeutic Inc

Neumedicines Inc

Novartis AG

Palatin Technologies Inc

Proximagen Ltd

Redx Pharma Plc

Ribomic Inc

Scholar Rock Inc

SciFluor Life Sciences LLC

SK Chemicals Co Ltd

Symic Biomedical Inc

Fibrosis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis-Pipeline Review, H2 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.

Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 29, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Fibrosis-Overview 7

Fibrosis-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Fibrosis-Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Fibrosis-Companies Involved in Therapeutics Development 28

Acceleron Pharma Inc 28

Aelis Farma SAS 28

Anima Biotech Ltd 28

Bristol-Myers Squibb Company 29

Cellmid Ltd 29

Clementia Pharmaceuticals Inc 30

Complexa Inc 30

Confo Therapeutics 31

EA Pharma Co Ltd 31

Five Prime Therapeutics Inc 31

Genfit SA 32

GlycoMimetics Inc 32

iBio Inc 33

Inception Sciences Inc 33

Isarna Therapeutics GmbH 34

Kadmon Corp LLC 34

Kalyra Pharmaceuticals Inc 34

Morphic Therapeutic Inc 35

Neumedicines Inc 35

Novartis AG 36

Palatin Technologies Inc 36

Proximagen Ltd 37

Redx Pharma Plc 37

Ribomic Inc 37

Scholar Rock Inc 38

SciFluor Life Sciences LLC 38

SK Chemicals Co Ltd 38

Symic Biomedical Inc 39

Fibrosis-Drug Profiles 40

ACE-2798-Drug Profile 40

AEF-0118-Drug Profile 41

AK-002-Drug Profile 42

Antisense RNAi Oligonucleotide to Inhibit HSP47 for Fibrosis-Drug Profile 43

CAB-101-Drug Profile 44

CALY-001-Drug Profile 46

CWHM-12-Drug Profile 47

Drugs for Fibrosis-Drug Profile 48

elafibranor-Drug Profile 49

G-XXX-Drug Profile 57

IB-DMD-Drug Profile 58

IBIOCFB-03-Drug Profile 59

ISTH-1106-Drug Profile 62

KL-01045-Drug Profile 63

Monoclonal Antibodies for Fibrosis-Drug Profile 64

Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis-Drug Profile 65

Monoclonal Antibody 2 for Fibrosis-Drug Profile 66

Monoclonal Antibody for Fibrotic Scar-Drug Profile 67

Monoclonal Antibody to Activate BMP7 for Fibrosis-Drug Profile 68

NCE-401-Drug Profile 69

Neumomir-Drug Profile 70

NMIL-121-Drug Profile 71

PAT-048-Drug Profile 75

phenylbutyrate-Drug Profile 76

PL-5028-Drug Profile 77

PRI-724-Drug Profile 78

Proteins for Central Nervous System Disorders and Fibrosis-Drug Profile 80

RBM-003-Drug Profile 81

RBM-007-Drug Profile 82

SB-061-Drug Profile 83

Small Molecule for Fibrosis-Drug Profile 85

Small Molecule for Fibrosis-Drug Profile 86

Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases-Drug Profile 87

Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease-Drug Profile 88

Small Molecule to Inhibit MGAT2 for Metabolic Disorders and Fibrotic Diseases-Drug Profile 89

Small Molecule to Inhibit MicroRNA for Vascular Fibrosis-Drug Profile 90

Small Molecule to Inhibit ROCK2 for Fibrotic Diseases-Drug Profile 91

Small Molecules for Fibrosis-Drug Profile 92

Small Molecules for Fibrosis-Drug Profile 93

Small Molecules for Fibrosis-Drug Profile 94

Small Molecules for Fibrosis-Drug Profile 95

Small Molecules for Fibrosis-Drug Profile 96

Small Molecules for Fibrosis and Inflammatory Diseases-Drug Profile 97

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis-Drug Profile 98

Small Molecules to Agonize GPCR for Fibrosis-Drug Profile 99

Small Molecules to Agonize RARG for Fibrosis-Drug Profile 100

Small Molecules to Antagonize Integrin Alpha V for Fibrosis-Drug Profile 101

Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease-Drug Profile 102

Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology-Drug Profile 103

SRI-31277-Drug Profile 104

ST-2001-Drug Profile 105

ST-2022-Drug Profile 106

Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology-Drug Profile 107

TTX-330-Drug Profile 108

X-165-Drug Profile 109

XOMA-089-Drug Profile 110

Fibrosis-Dormant Projects 111

Fibrosis-Product Development Milestones 114

Featured News & Press Releases 114

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118


List Of Figure

List of Figures

Number of Products under Development for Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Fibrosis-Pipeline by Acceleron Pharma Inc, H2 2017

Fibrosis-Pipeline by Aelis Farma SAS, H2 2017

Fibrosis-Pipeline by Anima Biotech Ltd, H2 2017

Fibrosis-Pipeline by Bristol-Myers Squibb Company, H2 2017

Fibrosis-Pipeline by Cellmid Ltd, H2 2017

Fibrosis-Pipeline by Clementia Pharmaceuticals Inc, H2 2017

Fibrosis-Pipeline by Complexa Inc, H2 2017

Fibrosis-Pipeline by Confo Therapeutics, H2 2017

Fibrosis-Pipeline by EA Pharma Co Ltd, H2 2017

Fibrosis-Pipeline by Five Prime Therapeutics Inc, H2 2017

Fibrosis-Pipeline by Genfit SA, H2 2017

Fibrosis-Pipeline by GlycoMimetics Inc, H2 2017

Fibrosis-Pipeline by iBio Inc, H2 2017

Fibrosis-Pipeline by Inception Sciences Inc, H2 2017

Fibrosis-Pipeline by Isarna Therapeutics GmbH, H2 2017

Fibrosis-Pipeline by Kadmon Corp LLC, H2 2017

Fibrosis-Pipeline by Kalyra Pharmaceuticals Inc, H2 2017

Fibrosis-Pipeline by Morphic Therapeutic Inc, H2 2017

Fibrosis-Pipeline by Neumedicines Inc, H2 2017

Fibrosis-Pipeline by Novartis AG, H2 2017

Fibrosis-Pipeline by Palatin Technologies Inc, H2 2017

Fibrosis-Pipeline by Proximagen Ltd, H2 2017

Fibrosis-Pipeline by Redx Pharma Plc, H2 2017

Fibrosis-Pipeline by Ribomic Inc, H2 2017

Fibrosis-Pipeline by Scholar Rock Inc, H2 2017

Fibrosis-Pipeline by SciFluor Life Sciences LLC, H2 2017

Fibrosis-Pipeline by SK Chemicals Co Ltd, H2 2017

Fibrosis-Pipeline by Symic Biomedical Inc, H2 2017

Fibrosis-Dormant Projects, H2 2017

Fibrosis-Dormant Projects, H2 2017 (Contd..1), H2 2017

Fibrosis-Dormant Projects, H2 2017 (Contd..2), H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Fibrosis Therapeutic Products under Development, Key Players in Fibrosis Therapeutics, Fibrosis Pipeline Overview, Fibrosis Pipeline, Fibrosis Pipeline Assessment


Companies

Acceleron Pharma Inc

Aelis Farma SAS

Anima Biotech Ltd

Bristol-Myers Squibb Company

Cellmid Ltd

Clementia Pharmaceuticals Inc

Complexa Inc

Confo Therapeutics

EA Pharma Co Ltd

Five Prime Therapeutics Inc

Genfit SA

GlycoMimetics Inc

iBio Inc

Inception Sciences Inc

Isarna Therapeutics GmbH

Kadmon Corp LLC

Kalyra Pharmaceuticals Inc

Morphic Therapeutic Inc

Neumedicines Inc

Novartis AG

Palatin Technologies Inc

Proximagen Ltd

Redx Pharma Plc

Ribomic Inc

Scholar Rock Inc

SciFluor Life Sciences LLC

SK Chemicals Co Ltd

Symic Biomedical Inc